Cabozantinib eradicates advanced murine prostate cancer by activating anti-tumor innate immunity

Several kinase inhibitors that target aberrant signaling pathways in tumor cells have been deployed in cancer therapy. However, their impact on the tumor immune microenvironment remains poorly understood. The tyrosine kinase inhibitor cabozantinib showed striking responses in cancer clinical trial p...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Discov
Главные авторы: Patnaik, Akash, Swanson, Kenneth D., Csizmadia, Eva, Solanki, Aniruddh, Landon-Brace, Natalie, Gehring, Marina P., Helenius, Katja, Olson, Brian M., Pyzer, Athalia R., Wang, Lily C., Elemento, Olivier, Novak, Jesse, Thornley, Thomas B., Asara, John M., Montaser, Laleh, Timmons, Joshua J., Morgan, Todd M., Wang, Yugang, Levantini, Elena, Clohessy, John G., Kelly, Kathleen, Pandolfi, Pier Paolo, Rosenblatt, Jacalyn M., Avigan, David E., Ye, Huihui, Karp, Jeffrey M., Signoretti, Sabina, Balk, Steven P., Cantley, Lewis C.
Формат: Artigo
Язык:Inglês
Опубликовано: 2017
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501767/
https://ncbi.nlm.nih.gov/pubmed/28274958
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0778
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы